All In MedTech

Device Trial Radar · NCT02097420

HALO: A Single Arm Prospective Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve

HALO Clinical Study: A Single Arm, Prospective, Non-randomized, Multi Center Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve

Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

May 7, 2015

Primary completion

Mar 2019

Study completion Jul 2023

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Mar 27, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to provide evidence of safety and effectiveness of the study valve. The rationale is to offer a replacement mitral valve for patients with anatomy that is too small for the currently commercially available valves ranging in size from 16mm to 37mm. 20 subjects were enrolled as part of the IDE cohort and an additional 3 were enrolled under continued access.

Conditions

  • Mitral Valve Disease
  • Damaged Mitral Valve
  • Malfunctioning Mitral Heart Valve
  • Mitral Valve Replacement

Interventions

  • Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart ValveDevice

    Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness Endpoint: Kaplan-Meier Percentage of Participants Who Remained Alive or Had Valve Explanted Due to Anatomical GrowthTime frame: 12 months
  2. Primary Effectiveness Endpoint: Peak Gradient as Assessed by EchocardiographyTime frame: 12 months
  3. Primary Effectiveness Endpoint: Mean Gradient as Assessed by EchocardiographyTime frame: 12 months

2 more outcomes with a free account

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Children's Hospital Los Angeles (USC)

    Los Angeles, California

21 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.